Article

No margin for nonadherence in CML patients receiving imatinib


 

Key clinical point: Compared with 90% adherence, a 100% adherence to imatinib was associated with a 2-fold increase in achieving or maintaining treatment response in patients with chronic myeloid leukemia (CML), highlighting the urgent need to assess and promote patient adherence.

Major finding: A 90-day imatinib pill-count adherence of 100% vs. 90% increased the probabilities of achieving complete hematological response by 2.25-fold (probability of treatment response [pTR] 0.8416 vs. 0.3746), complete cytogenic response by 2.24-fold (pTR 0.8335 vs. 0.3714), major molecular response by 1.95-fold (pTR 0.7698 vs. 0.3938), and optimal response by 2.35-fold (pTR 0.8236 vs. 0.3512).

Study details: Findings are from a post hoc analysis of the ADAGIO study including 169 patients with CML.

Disclosures: This study did not receive any specific funding. Some investigators reported being equity shareholders and employees of or receiving honoraria from various sources including Novartis which funded the ADAGIO study.

Source: Obeng-Kusi M et al. Leuk Res. 2021;111:106734 (Oct 21). Doi: 10.1016/j.leukres.2021.106734.

Recommended Reading

Risk factors associated with COVID-19 mortality in CML patients
MDedge Hematology and Oncology
CML-CP: Elevated creatine kinase levels during first-line TKI treatment associated with improved survival
MDedge Hematology and Oncology
Need for more precise TKI dosing in real-world CML-CP patients
MDedge Hematology and Oncology
Ten-year follow-up continue to support nilotinib in Japanese patients with newly diagnosed CML-CP
MDedge Hematology and Oncology
CML: Better response with first-line new-generation TKI therapy vs. imatinib
MDedge Hematology and Oncology
Allo-HCT outcomes in CML patients previously treated with 2G-TKIs
MDedge Hematology and Oncology
Frontline dasatinib therapy is effective and well tolerated in older patients with CML-CP
MDedge Hematology and Oncology
Global rise in incident CML calls for better patient management
MDedge Hematology and Oncology
Clinical Edge Journal Scan Commentary: CML November 2021
MDedge Hematology and Oncology
New trials in leukemia: Could your patient benefit?
MDedge Hematology and Oncology